Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Protalix BioTherapeutics (PLX) over the last 15 years, with Q1 2025 value amounting to $76.6 million.

  • Protalix BioTherapeutics' Shares Outstanding (Diluted Average) rose 489.54% to $76.6 million in Q1 2025 from the same period last year, while for Mar 2025 it was $76.6 million, marking a year-over-year increase of 489.54%. This contributed to the annual value of $48.5 million for FY2022, which is 981.4% up from last year.
  • As of Q1 2025, Protalix BioTherapeutics' Shares Outstanding (Diluted Average) stood at $76.6 million, which was up 489.54% from $73.3 million recorded in Q2 2024.
  • Over the past 5 years, Protalix BioTherapeutics' Shares Outstanding (Diluted Average) peaked at $83.2 million during Q2 2023, and registered a low of $39.9 million during Q1 2021.
  • For the 5-year period, Protalix BioTherapeutics' Shares Outstanding (Diluted Average) averaged around $56.1 million, with its median value being $48.5 million (2022).
  • Per our database at Business Quant, Protalix BioTherapeutics' Shares Outstanding (Diluted Average) surged by 7579.6% in 2023 and then crashed by 1188.98% in 2024.
  • Over the past 5 years, Protalix BioTherapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $44.1 million in 2021, then increased by 9.81% to $48.5 million in 2022, then surged by 71.65% to $83.2 million in 2023, then dropped by 11.89% to $73.3 million in 2024, then rose by 4.51% to $76.6 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $76.6 million for Q1 2025, versus $73.3 million for Q2 2024 and $73.0 million for Q1 2024.